id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-N-3273-0001,FDA,FDA-2026-N-3273,"Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments",Notice,Request for Comments,2026-04-15T04:00:00Z,2026,4,2026-04-15T04:00:00Z,2026-07-24T03:59:59Z,2026-04-15T17:05:22Z,2026-07248,1,0,09000064b9282224